Sign in

You're signed outSign in or to get full access.

Aaron Ryskin

Managing Director and Equity Research Analyst at Bank of America

Aaron Ryskin is a Managing Director and Equity Research Analyst at Bank of America Securities, specializing in life science tools & diagnostics and animal health sectors. He covers companies such as Guardant Health, participating in earnings calls to analyze growth drivers like screening products and reimbursement trends, though specific performance metrics like success rates or TipRanks rankings are not publicly detailed in available sources. Ryskin has been with Bank of America in his current role, noted in 2025 BIO International Convention program, with prior experience substituting for senior analyst Michael Ryskin in calls, suggesting a trajectory in equity research; professional credentials include standard FINRA registrations typical for managing directors in securities research.

Aaron Ryskin's questions to Guardant Health (GH) leadership

Question · Q4 2025

Aaron Ryskin asked about the factors influencing the Shield guidance, including whether Q4 volume growth was an anomaly, embedded conservatism, and the timing of impacts from Quest and PathGroup collaborations.

Answer

Co-CEO AmirAli Talasaz explained the thoughtful approach to guidance, acknowledging Q1 seasonality but expecting strong year-over-year growth. He clarified that Quest and PathGroup benefits, particularly from co-promotion and ACS guideline inclusion, are largely considered upside to the current guidance.

Ask follow-up questions

Fintool

Fintool can predict Guardant Health logo GH's earnings beat/miss a week before the call